Axel Bolte
Founder chez INOZYME PHARMA, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Axel Bolte is the founder of Inozyme Pharma, Inc. (founded in 2015) and holds the title of Director.
He is currently the Deputy Chairman-Supervisory Board at Nabriva Therapeutics GmbH since 2007 and a Director at Tripex Pharmaceuticals LLC.
Mr. Bolte has also held former positions as Vice Chairman at Kolltan Pharmaceuticals, Inc., Independent Director at PTC Therapeutics, Inc. (2013-2014), Director at Lux Biosciences, Inc., Director at ZP Opco, Inc., Director at Adnexus, Director at Newron Pharmaceuticals SpA (2005-2008), Director at Enanta Pharmaceuticals, Inc. (2005-2013), Director at Affinium Pharmaceuticals Ltd., Director at MPEX Pharmaceuticals, Inc. (2006-2011), Independent Director at IVERIC bio, Inc. (2007-2023), Independent Director at Allena Pharmaceuticals, Inc. (2014-2019), Independent Director at Nabriva Therapeutics Plc (2017-2018), Investment Advisor at HBM Partners AG (2013-2017), Principal at Serono SA, Investment Manager at New Medical Technologies AG (2001-2003), Managing Member at Healthcare Advisors GmbH (2017-2019), and Investment Manager at Nmt New Medical Technologies AG (2001-2003).
Mr. Bolte's education includes an undergraduate degree from the University of Cambridge, an MBA from the University of St. Gallen, and a graduate degree from the Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INOZYME PHARMA, INC.
0,43% | 13/06/2023 | 266 696 ( 0,43% ) | 2 M $ | 31/03/2024 |
Postes actifs de Axel Bolte
| Sociétés | Poste | Début |
|---|---|---|
| INOZYME PHARMA, INC. | Founder | 01/09/2015 |
Tripex Pharmaceuticals LLC
 Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | Director/Board Member | - |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Director/Board Member | 01/01/2007 |
Anciens postes connus de Axel Bolte
| Sociétés | Poste | Fin |
|---|---|---|
| IVERIC BIO, INC. | Director/Board Member | 11/07/2023 |
| Healthcare Advisors GmbH | Corporate Officer/Principal | 01/09/2019 |
| ALLENA PHARMACEUTICALS, INC. | Director/Board Member | 05/06/2019 |
| NABRIVA THERAPEUTICS PLC | Director/Board Member | 01/08/2018 |
| PTC THERAPEUTICS, INC. | Director/Board Member | 01/07/2014 |
Formation de Axel Bolte
| University of Cambridge | Undergraduate Degree |
| University of St. Gallen | Masters Business Admin |
| Swiss Federal Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| NEWRON PHARMACEUTICALS S.P.A. | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| INOZYME PHARMA, INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| ALLENA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Lux Biosciences, Inc.
 Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Health Technology |
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Health Technology |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
Serono SA
 Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
| New Medical Technologies AG | Finance |
Adnexus
 Adnexus Pharmaceuticals: MajorHealth Technology Adnexus engages in the development of Adnectins biologics and medicines in the United States. The company was founded by Frank D. Lee on September 16, 2002 and is headquartered in Waltham, MA. | Health Technology |
Affinium Pharmaceuticals Ltd.
 Affinium Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Tripex Pharmaceuticals LLC
Tripex Pharmaceuticals LLC Pharmaceuticals: OtherHealth Technology Tripex Pharmaceuticals LLC provides pharmaceutical services. The company is headquartered in Encinas, CA. | Health Technology |
| Healthcare Advisors GmbH | |
| Nmt New Medical Technologies AG |
